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3 
ABSTRACT 
 
Objectives 
The aim of our study was to develop a simplified radiological score that could assess 
clinical disease severity in bronchiectasis. 
 
Methods  
The BRICS (Bronchiectasis Radiologically Indexed CT Score) was devised based 
on multivariable analysis of the Bhalla score and their ability in predicting clinical 
parameters of severity. The score was then externally validated in 6 centers in 302 
patients. 
 
Result 
184 HRCT scans were scored for the validation cohort. In a multiple logistic 
regression model, disease severity markers significantly associated with the Bhalla 
score were percentage predicted FEV1, sputum purulence and exacerbations requiring 
hospital admission. Components of the Bhalla score that were significantly associated 
with the disease severity markers were bronchial dilatation and number of 
bronchopulmonary segments with emphysema. The BRICS was developed with these 
two parameters. The receiver operator curve values for BRICS in the derivation 
cohort were 0.79 for percentage predicted FEV1, 0.71 for sputum purulence and 0.75 
for hospital admissions/year; and 0.81, 0.70 and 0.70 respectively in the validation 
cohort. Sputum free neutrophil elastase was significantly elevated in the group with 
emphysema on CT. 
 
Conclusion 
A simplified CT scoring system can be used as an adjunct to clinical parameters to 
predict disease severity in patients with idiopathic and post-infective bronchiectasis. 
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TEXT 
 
INTRODUCTION 
 
High resolution CT scan of the thorax (HRCT) remains the imaging gold standard for 
diagnosing bronchiectasis and for diagnosis patients should have bronchial dilatation 
at least greater than the adjacent pulmonary artery [1-5]. In 1991, Bhalla et al 
published a detailed scoring system to quantify structural lung abnormalities in 
patients with cystic fibrosis using thin section CT scans [6]. Subsequent to that, Reiff 
et al developed a scoring system that described the site, type and extent of 
bronchiectasis and since then ‘?the modified Reiff score‘?is frequently used in studies 
[7]. The Bronchiectasis Severity Index and FACED score were devised using several 
clinical parameters including number of lobes affected by bronchiectasis on CT scan, 
to predict severity and prognosis in bronchiectasis [8,9].  However, both studies 
included a heterogeneous population of bronchiectasis with a variable smoking 
history. Additionally, the radiology scoring in both scores only took into account the 
number of lobes affected by bronchiectasis [9] and the presence of cystic 
bronchiectasis [8]. Both these scores are easy to use but are multidimensional.  
 
Hence, the role of CT imaging in defining bronchiectasis phenotypes above and 
beyond conventional characterization remains to be fully determined. CT scanning as 
a phenotypical marker of airway disease is yet to be established and no studies have 
stratified for the etiology of bronchiectasis [10].  
 
The aim of our study was to develop a simple CT score that could assess clinical 
disease severity in idiopathic and post infective bronchiectasis in a cohort with limited 
smoking history, using multivariable models. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
5 
METHODS 
 
Study design 
A prospective study was carried out between 2006 and 2013, at the Royal Infirmary 
of Edinburgh, United Kingdom. All new adult patients attending the bronchiectasis 
clinic routinely had a non contrast HRCT acquired with 1mm slices as a single breath 
hold on a 64 multi-slice CT scanner (Toshiba Medical Systems, Tokyo Japan). 
Clinical parameters recorded at the time of the CT scan were: spirometry; degree of 
sputum purulence (mucoid =1, mucopurulent =2 and purulent ≥? 3) [11]; qualitative 
sputum microbiology (baseline, 6 and 12 months following); exacerbations requiring 
antibiotics and hospital admissions for bronchiectasis exacerbations in the following 
year. Neutrophil elastase was measured in sputum when available.  
 
Ethical approval 
Caldicott approval was given for conducting the study. 
 
Imaging 
Across all centers, CT scans were obtained using a 64-slice multiple detector CT 
scanner (Toshiba/ Seimens/ Phillips) or a 4-slice multiple detector CT scanner 
(Toshiba/ Seimens/ Phillips). All scans were reconstructed using a high spatial 
frequency, B70 kernel. All patients were scanned from lung apices to bases, supine, at 
full inspiration, with 1·0mm section thicknesses at either 1mm or 10mm intervals 
using a peak voltage of 120kVp with tube current modulation (range 30-140mA). 
Images were viewed at window settings optimized for the assessment of the lung 
parenchyma (width 1500 Houndsfield Units (H.U.); level -500 H.U.). 
Across centers, all images were reviewed by a consultant radiologist with experience 
of reporting HRCT and a consultant respiratory physician with a major interest in 
bronchiectasis. A consensus score was produced using the criteria outlined below.  
Bronchiectasis was present when one or more of the criteria were fulfilled: (1) 
internal diameter of the bronchus greater than that of the adjacent pulmonary artery; 
(2) a lack of tapering of the bronchial lumen towards the periphery. 
In the derivation cohort, CT scans were scored independently and a kappa coefficient 
was calculated. 
 
Patients (derivation and validation cohort) 
Inclusion criteria: Patients having a clinical diagnosis of bronchiectasis with regular 
cough and sputum production with or without recurrent chest infections and cause of 
bronchiectasis being idiopathic or post infective as per British Thoracic Society 
guidelines [10]. Exclusion criteria: Alpha 1 anti trypsin deficiency, smoking history of 
more than 5 pack years, current smoker or ex-smoker <1 year. 
 
Scoring the CT scans 
Bhalla and modified Reiff scores were calculated on all patients that met inclusion 
and exclusion criteria. Both of these scores were jointly carried out by consensus by a 
chest physician and radiologist both blinded to the clinical status of the patient. The 
Bhalla score was calculated by scoring each of the 9 categories and then adding up the 
total score [6]. The total points were then subtracted from 25 to obtain the Bhalla 
score. The maximum points that can be obtained in a Bhalla score is 22 (prior to 
subtracting from 25; Appendix 1). 
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The modified Reiff score [7] used (0-18) was based on the number of lobes 
(maximum 6 including lingula) and the severity of bronchial dilatation in comparison 
to the adjacent vessel (0=no bronchiectasis; 1= 1-2 times; 2= 2-3 times; 3= greater 
than three times).  
 
Subdivision of the CT Scores  
The total range for the Bhalla score is from 3-25, where a lower score indicates more 
severe radiological bronchiectasis. This score was subdivided into mild (16-25), 
moderate (9-15) and severe (3-8).  
The total range of the Modified Reiff Score is from 0-18. This was subdivided into 
mild (1-6); moderate (7-12) and severe (13-18).  
 
BRICS 
The BRICS (Bronchiectasis Radiologically Indexed CT Score) score (detailed in 
the results section) would be devised based on multivariable analysis of the Bhalla 
score and their ability in predicting clinical parameters of severity.  
 
External validation of the BRICS 
The BRICS was externally validated by 6 centers across the UK and Europe- by a 
chest physician and a radiologist. The score was validated in 50 consecutive 
individual patients from each center (except Dundee and London, UK- where the 
score was validated in 60 and 42 patients respectively). The protocols for imaging was 
similar to our center, and was viewed in the respective PACS version available at 
various centers. 
 
Sputum neutrophil elastase 
Sputum neutrophil elastase was measured when available in the derivation cohort. 
Sputum was ultracentrifuged at 50000 g for 90 min at 4°C. The colloidal solution 
phase was stored at –70°C until needed for analysis of the activity of free neutrophil 
elastase. We measured free elastase activity by spectrophotometry with a synthetic 
substrate (methoxysuccinyl-Ala-Ala-Pro-Val paranitroanilide; Sigma, Gillingham, 
UK) [14-16]. 
 
BSI and FACED score 
The BSI (Bronchiectasis Severity Index) and the FACED [10] score were calculated 
on all patients in the derivation and validation cohort (except in London cohort). In 
the BSI score- a score between 0-4 indicated mild disease, 5-8 moderate and 9 or over 
severe disease. In the FACED score- a score between 0-2 indicates mild disease, 3-4 
moderate disease and 5-7 severe disease.  
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STATISTICAL ANALYSIS 
Statistical analysis was performed using graph pad PRISM, version 5 (GraphPad 
Software; San Diego, California). Parametric and non-parametric data are presented 
as mean (standard error of mean-SEM) and median (interquartile range- IQR). 
Adjustment for potential confounders was achieved using multivariable logistic 
regression. Multivariable regression models were constructed by including 
demographic (age, gender, co-morbidities, smoking history‘? as listed in Table 1) and 
clinical characteristics (FEV1 >80% predicted, FEV1 50-80% predicted, FEV1 <50% 
predicted, colonization with Pseudomonas aeruginosa and/or enteric gram negative 
organisms, colonization with other potential pathogenic organisms, sputum purulence, 
bronchiectasis exacerbations, hospital admissions for bronchiectasis exacerbations) to 
assess independent clinical factors that predict a severe Bhalla score;  with the Bhalla 
score as the dependent variable. Following this, a logistic regression was performed to 
assess independent factors from the Bhalla score that predicted clinical disease 
severity. ROC analyses of all three scores (Bhalla, modified Reiff and BRICS) to the 
clinical severity markers were done. One-way ANOVA (with Bonferroni‘?s correction 
for multiple comparisons) was used to compare the mild, moderate and severe sub-
scores of the Bhalla, modified Reiff score and the BRICS to each of the severity 
parameters. A Mann Whitney U and chi square analysis was done to compare the free 
neutrophil elastase in the derivation cohort. 
A one-way ANOVA (with Bonferroni‘?s correction for multiple comparisons) and 
ROC analysis of the collated independent data was done to validate BRICS 
externally. 
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RESULTS 
184 consecutive CT scans of patients with idiopathic or post infective etiology, were 
analyzed in the derivative cohort. Baseline characteristics of the study patients in all 
the cohorts, including the validation cohorts are shown in Table 1.  
 
 Edinburgh 
 
Dundee London Italy Belgium Spain Cambridge 
N 
 
184 60 42 50 50 50 50 
Age 
 
65  
(57-72) 
70.5 
(65-76) 
67 
(58-73) 
67 
(67-73) 
61 
(44-71) 
66.5 
(51-77) 
62 
(48-73) 
Gender 
(Female %) 
59% 63% 76% 68% 76% 84% 68% 
Etiology 
Idiopathic 
 
Post infective 
 
92  
(50%) 
92  
(50%) 
 
44 
(73.3%) 
16 
(26.7%) 
 
16 
(38%) 
26 
(62%) 
 
17 
(34%) 
33 
(66%) 
 
31 
(62%) 
19 
(38%) 
 
38 
(76%) 
12 
(24%) 
 
14 
(28%) 
36 
(72%) 
Chronic  
Colonization* 
116  
(63%) 
32 
(53.3%) 
25 
(59.5%) 
36 
(72%) 
10 
(20%) 
13 
(26%) 
20 
(40%) 
Colonization 
with  
P. aeruginosa 
50  
(43%) 
5  
(8.3%) 
17 
(40.4%) 
15 
(30%) 
 
6 
(12%) 
9 
(18%) 
12 
(24%) 
Comorbidities 
IHD 
 
Previous 
malignancy 
 
6  
(3%) 
6  
(3%) 
 
10 
(16.7%) 
4  
(6.7%) 
 
1  
(2.3%) 
0 
 
2  
(4%) 
6  
(12%) 
 
2  
(4%) 
3  
(6%) 
 
3 
(6%) 
6 
(12%) 
 
3 
(6%) 
6 
(12%) 
ICS 
 
132  
(72%) 
30  
(50%) 
26  
(62%) 
19 
(38%) 
33 
(66%) 
38 
(76%) 
40 
(80%) 
FEV1 
(L) 
1.85  
(1.36-2.4) 
1.83 
(1.3-2.4) 
1.5  
(1.1- 1.9) 
1.8 
(1.1-
2.4) 
2 
(1.4-2.5) 
1.8 
(1.1-
2.3) 
1.9 
(1.4-2.7) 
% predicted 
FEV1 
77%  
(61-95%) 
83% 
(58- 
104) 
66% 
(47-80) 
88% 
(69-
101) 
77% 
(62- 90) 
76% 
(54-97) 
80% 
(69-94) 
Table 1. Baseline characteristics of the derivation cohort and independent cohorts 
*chronic colonization defined as isolation of pathogenic organism at least two times 
when clinically stable in the year following CT scanning; Pathogens can up to more 
than 100% in view that there can be combined pathogens or different pathogens  
isolated at different time points; ICS= inhaled corticosteroid; IHD= ischemic heart 
disease; FEV1= Forced expiratory volume in 1 second. 
 
Intra class coefficient 
The kappa coefficient between the chest physician and chest radiologist was 0.88 
(95% CI 0.82-0.94). 
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Clinical severity markers associated with the Bhalla score (Table 2) 
In a logistic regression model, factors significantly associated with the Bhalla score 
were FEV1 <50% predicted, sputum purulence and hospital admissions.  
  
 Estimate Std. Err. Z-Stat P-Value 
Gender (male) -0.1 0.5 <-1 0.8 
Age>65 years -0.3 0.5 <-1 0.5 
FEV1 50-80% 
predicted -0.6 1.1 <-1 0.5 
FEV1<50% 
predicted -2.5 0.6 -4 <0.0001 
Purulent sputum  -1.0 0.5 -2 0.04 
Chronic 
colonization -1.4 0.8 -2 0.08 
Chronic 
colonization with 
P.aeruginosa s 
enteric gram 
negative 
organism 
 
0.7 
 
 
 
 
0.8 
 
 
 
 
<1 
 
 
 
 
0.4 
 
 
 
 
Colonization 
with other PPMs 1.4 0.7 2 0.06 
Hospital 
admission 
-2.2 
 
0.6 
 
-3.5 
 
0.0006 
 
≥?≥?  3 
exacerbations/ 
year 
0.5 
 
0.5 
 
1 
 
0.3 
 
 
 
Table 2. Logistic regressions using Bhalla score with severity parameters. FEV1= 
Forced expiratory volume in 1 second; PPM= potential pathogenic microorganisms. 
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Factors of the Bhalla score associated with clinical severity parameters 
The three clinical disease severity markers associated with the Bhalla score were 
FEV1 <50% predicted, sputum purulence and hospital admissions (Table 2). Of the 9 
components of the Bhalla score (Appendix 1), only the degree of bronchial dilatation 
and number of bronchopulmonary segments with emphysema were independently 
associated with FEV1 <50% predicted, sputum purulence and hospital admissions (see 
Table 3), by logistic regression analysis. Emphysema was diagnosed by assessing the 
lung parenchyma on lung windows and classified as para-septal, centrilobular or 
panacinar based on the accepted morphological diagnostic criteria [12]. 
 
Variable 
 
P value 
Dependent variable: FEV1 <50% 
 
Bronchial dilatation 0.04 
Dependent variable: Hospital admissions 
 
Number of bronchopulmonary segments 
with emphysema 
0.02 
Dependent variable: Sputum purulence 
 
Number of bronchopulmonary segments 
with emphysema 
0.03 
 
Table 3. Logistic regression of the Bhalla score.  
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Simplified scoring system 
The BRICS (Bronchiectasis Radiologically Indexed CT Score) was developed by 
combining the parameters of bronchial dilatation and number of bronchopulmonary 
segments with emphysema, as these two components of the Bhalla score were 
significantly associated with clinical severity markers. The new score ranges from 0 
to 5, where 1 indicates mild disease, 2-3 indicates moderate disease and >3 indicates 
severe disease (Table 4).  
 
Score 
 
0 1 2 3 
Bronchial dilatation Absent Mild 
(lumen just > 
diameter of 
adjacent 
vessel) 
Moderate 
(lumen 2-3 
times > 
diameter of 
adjacent 
vessel) 
Severe 
(lumen >3 
times  
diameter of 
adjacent 
vessel) 
Number of 
bronchopulmonary 
segments with 
emphysema 
Absent 1-5 >5  
 
Table 4. BRICS derived from combining bronchial dilatation with number of 
bronchopulmonary segments with emphysema. 
 
ROC analysis of individual radiology scores to clinical severity parameters 
The receiver operator curves of the Bhalla, modified Reiff and the BRICS in 
predicting the clinical severity parameters- percent predicted FEV1, sputum purulence 
and hospital admissions were calculated.  The ROC values for the Bhalla score were 
0.89 for percentage predicted FEV1, 0.70 for sputum purulence and 0.62 for hospital 
admissions per year. The ROC values for the modified Reiff score were 0.58 for 
percentage predicted FEV1, 0.75 for sputum purulence and 0.57 for hospital 
admissions per year. The ROC values for the BRICS were 0.79 for percentage 
predicted FEV1, 0.71 for sputum purulence and 0.75 for hospital admissions per year. 
 
Comparison of the BRICS to the BSI and FACED score  
The ROC values for BSI were 0.58 for percentage predicted FEV1, 0.54 for sputum 
purulence and 0.61 for hospital admissions per year. The ROC values for the FACED 
score were 0.53 for percentage predicted FEV1, 0.63 for sputum purulence and 0.55 
for hospital admissions per year. 
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BRICS correlates with clinical disease severity markers (Figure 1) 
The Bhalla (p<0.0001) and the BRICS (p=0.004) are significantly related to 
percentage predicted FEV1. The modified Reiff score (p<0.0001) and the BRICS 
(p=0.008) are significantly related to the sputum purulence. The Bhalla score 
(p=0.005) and the BRICS (p=0.0001) are significantly related to hospital admissions 
per year. The BRICS is significantly related to all three clinical disease severity 
markers.  
 
 
 
Free neutrophil elastase 
Sputum was available in 113 patients of the derivation cohort. Of these, 22 (19%) had 
emphysema on their CT scans and 91 (81%) did not. The mean (SEM) elastase in the 
group that had emphysema on the CT san was 60.6 ng/ml (±13.7) and in the other 
group was 7.6 ng/ml (±1.6), p<0.0001 (figure 2).  
 
 
 
Validation of the BRICS in independent cohorts 
 
The baseline characteristics of the independent cohorts are described in table 1. The 
data from the independent cohorts was collated and the BRICS calculated. 
Cumulatively, percent predicted FEV1 (p<0.0001), sputum purulence (p=0.0007) and 
hospital admissions (p<0.0001) were all significantly related to the BRICS (figure 3). 
The ROC curve value for percent predicted FEV1 was 0.81, for sputum purulence 
0.70 and hospital admissions 0.70.  The results were in similar in each validation 
center.  
 
BRICS severity compared to severity of BSI and FACED  
On combining data from both the derivation and validation cohort, BRICS severity 
was calculated and the corresponding BSI and FACED scores were tabulated. There 
was a significant association of the severity of the BRICS to the severity of the BSI 
and FACED score, p<0.0001 for both scores (figure 4).  
 
 
Emphysema on CT scan 
Combining the data from all centers, emphysema was reported in 50% (±15.6)  of the 
cohort. Data on the type of emphysema was available from 3 centers (Belgium, 
Edinburgh and London). A total of 48 scans with emphysema sub type were analyzed 
across these centers. Panacinar emphysema was present in 31 (64%), centrilobular in 
9 (19%) and paraseptal in 8 (17%) of the cohort.  
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DISCUSSION 
This is the first multi center international study to develop a radiological scoring 
system for use in idiopathic or post infective bronchiectasis, in a cohort with limited 
smoking history. In this study, we developed a simplified scoring system of CT scans 
in patients with bronchiectasis and found that this score was significantly associated 
with clinical parameters of disease severity. The BRICS was devised using parameters 
of bronchial dilatation and number of bronchopulmonary segments with emphysema 
on HRCT scans of 184 patients in the derivation cohort, with either idiopathic or post 
infective bronchiectasis. The score ranges from 0 to 5 in this scoring system, where a 
higher score is indicative of increasing disease severity. The score was significantly 
associated to percentage predicted FEV1, sputum purulence and hospital admissions 
for bronchiectasis exacerbations. In addition, we found that free neutrophil elastase, 
an established marker of neutrophilic airway inflammation in bronchiectasis [13,14], 
was significantly higher in the patients who had emphysema on their CT scans. The 
BRICS was compared to the existing Bhalla score and modified Reiff scores and was 
found to be as reliable and predictive of disease severity compared to these other 
scores. This score was then externally validated in a cohort of 302 patients across 6 
centers in Europe. The results across these 6 centers were similar and in keeping with 
the derivation cohort. To the authors‘?best knowledge this is the first simplified 
radiological score that has been developed to assess disease severity in patients with 
idiopathic/post-infective bronchiectasis. 
 
The BSI and FACED score were not significantly associated with percentage 
predicted FEV1, sputum purulence and hospital admissions for bronchiectasis 
exacerbations, but then, these two scores were not designed for the above stated end 
points. Hence, the BRICS is the first radiological severity score correlating with 
significantly with clinical parameters that can risk assess for severity.  
 
There are currently no markers to predict radiological disease severity in 
bronchiectasis. The clinical parameters of severity that were statistically significant in 
the multiple regression models have been demonstrated to be of significance in 
previous studies. It is well established that FEV1 is an important functional marker of 
pulmonary disease. We have previously demonstrated that sputum purulence is 
associated with disease severity in bronchiectasis [11]. It seems logical that if a 
patient requires repeated hospital admissions for bronchiectasis exacerbations as 
defined by the BTS guidelines [10], it indicates that the patient has more severe 
disease. In addition, in the Bronchiectasis Severity Index, the authors have 
demonstrated that prior hospital admissions and FEV1 <30% predicted are 
independent predictors of hospital admissions and mortality in bronchiectasis [8]. 
 
In this study we were able to demonstrate that the new simplified BRICS can predict 
disease severity, based on radiological appearances alone. In addition, sub divisions of 
the BRICS demonstrated that an increasing score is associated with increasing disease 
severity. Patients with a higher score on the BRICS had lower FEV1, more purulent 
sputum and increased hospital admissions for bronchiectasis exacerbations. 
Validation of the BRICS internationally showed that this was a simple but robust 
scoring system that can be used in day to day clinical practice. 
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Free neutrophil elastase was significantly higher in patients with emphysema on CT 
scan, in the derivation cohort. This is in keeping with data published in the literature 
[13,14]. Loubeyre et al [15] had demonstrated that there was a high prevalence of 
emphysema in bronchiectasis. Activation of matrix metalloproteinase by free 
neutrophil elastase has been shown to be one of the mechanisms of driving structural 
lung damage in early cystic fibrosis [16]. There is evidence to support that unopposed 
neutrophil elastase activity has come to be implicated in the pathobiology of many 
lung diseases, particularly in chronic obstructive lung disease. Known for its matrix-
degrading capacity and broad substrate repertoire, there is evidence to hypothesize 
that enhanced neutrophil elastase predominance over its natural inhibitors may result 
in, or at perhaps intensify, pathologic states such as fibrosis and emphysema [17].  
 
The two components defining the BRICS have been used in studies before. Bronchial 
dilatation is the classic radiological feature, which defines bronchiectasis on CT, 
scans. Although bronchial dilatation is associated with asthma, chronic bronchitis and 
pulmonary fibrosis, we can safely confirm that as our study was conducted in a well 
defined cohort of patients with either idiopathic or post infective bronchiectasis, 
(which are the two most common causes of bronchiectasis [18]), bronchial dilatation 
represented bronchiectasis. Loubeyre et al demonstrated emphysema in the CT scans 
of 90 consecutive patients with bronchiectasis and concluded that there was a high 
prevalence of emphysema in bronchiectasis patients [15].  
 
HRCT is a sensitive non-invasive technique for demonstrating bronchiectasis. The 
need for the creation of scoring systems comes from the fact that CT as a test depicts 
structural abnormalities in great detail but is a qualitative image, and the extent of the 
abnormality has to be quantified as a score in order to be used in statistical analysis 
[19]. Association studies between CT scans and clinical parameters- mostly lung 
physiology- have been conducted previously [20,21]. These studies have used the 
Bhalla score, the modified Reiff score or a simplified score that the authors have 
agreed upon by consensus. Airflow limitation can be seen in more advanced 
bronchiectasis [27,28]. Studies have demonstrated that airflow obstruction in 
bronchiectasis is linked to evidence of structural abnormality on CT scans [9,21,24]. 
The BRICS and our study findings corroborated with this.  
 
In summary, to the authors‘?best knowledge, this is the first international multi center 
simplified scoring system designed for use in idiopathic or post infective 
bronchiectasis. This is a useful clinical tool to assess radiological and clinical severity 
in bronchiectasis. This study is not confounded by other etiologies of bronchiectasis 
and pertains to a cohort with limited smoking history. The significantly higher levels 
of the neutrophil elastase in the cohort with emphysema on the CT scans compared to 
those with no emphysema, suggests that elastase is perhaps one of the possible causes 
for emphysema in this group.  There was significant association of the BRICS to the 
BSI and FACED.  The BRICS may be used to follow up patients longitudinally and 
hence be a useful research tool for future studies. In addition radiological scores could 
be used as an adjunct to clinical assessment in categorizing patients into disease 
severity groups, which could then guide management.  
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LIMITATIONS 
This study has been conducted in a cohort where the patients had idiopathic or post 
infective bronchiectasis. Bronchiectasis due to other etiologies need further study.  
 
CONCLUSION 
We have developed and validated a simplified CT scoring system based on degree of 
bronchial dilatation and number of bronchopulmonary segments with emphysema, in 
patients with idiopathic and post infective bronchiectasis, with limited smoking 
history.  
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
e-Table 1. Bhalla Score 
Category 0 1 2 3 
Severity of 
bronchiectasis 
Absent Mild 
(lumen just > 
diameter of 
adjacent vessel) 
Moderate 
(lumen 2-3 
times > 
diameter of 
adjacent vessel) 
Severe 
(lumen >3 times  
diameter of 
adjacent vessel) 
Peribronchial 
thickening 
Absent Mild 
(wall thickness = 
diameter of 
adjacent vessel) 
Moderate 
(wall thickness  
≤ 2 times 
diameter of 
adjacent vessel) 
Severe 
(wall thickness>2 
times  diameter 
of adjacent 
vessel) 
No. of 
bronchopulmonary 
segments involved 
Absent 1-5 6-9  
Extent of mucus 
plugging 
Absent 1-5 6-9  
Sacculations or 
abscesses 
Absent 1-5 6-9  
Generations of 
bronchial divisions 
involved 
Absent Up to 4th generation Up to 5th 
generation 
> 6th generation 
No. of bullae Absent Unilateral; not >4 Bilateral; not >4 >4 
No. of 
bronchopulmonary 
segments with 
emphysema 
Absent 1-5 >5  
Collapse or 
consolidation  
Absent Subsegmental Segmental or 
lobar 
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